Sher Institute Founder, Geoffrey Sher has long been a pioneer in the field and has, along with SIRM colleagues, introduced:

1982: First to recommend the exclusive use of gonadotropins to stimulate follicular development for IVF

1983: First to introduce Intrauterine Insemination (IUI) of washed sperm for treating certain forms of infertility.

1989: First to report on ultrasound appearance and thickness of the uterine lining (endometrium) as a predictor of IVF success.

1993: First to introduce the technique of “Prolonged Coasting” for cases of Severe Ovarian Hyperstimulation. This treatment protocol has virtually eliminated the life-endangering effects of this condition as well as eliminating the need to cancel the patient’s IVF cycle.

1994: First to identify and treat immune factors affecting implantation potential of embryos in certain women.

1997: First to introduce Viagra to enhance the thickness of the uterine lining in IVF patients.

1998: First to recommend the selective use of intravenous gamma globulin for the treatment of certain forms of immunologic implantation dysfunction in IVF.

2000: First to introduce a new protocol of ovarian stimulation, the agonist/antagonist conversion protocol (A/ACP) to improve egg/embryo quality in response to gonadotropin stimulation. This also led to the addition of advanced “priming” with Estradiol Valerate (A/ACP-E2V) to further augment the response of women with reduced ovarian reserve ( “poor responders”).

2003: First to measure soluble Human Leukocyte Antigen-G (sHLA-G) in the media surrounding early individual embryos and use this genetic marker to identify the “best individual embryos” (the ones that are most likely to implant and produce a viable pregnancy) for transfer to the uterus.

2007: First to show, by using a new genetic test, that an embryo resulting from fertilization of a euploid egg (i.e. an egg that has all of its chromosomes present), has a much improved ability to implant successfully and produce a normal baby. This method which tests egg/embryo “competence” is likely to vastly improve IVF results and lead to single embryo transfers, thereby minimizing the risk of multiple pregnancies.

2008: First to introduce newly pioneered developments in the field of oocyte cryopreservation (egg freezing) utilizing CGH to identify chromosomally “normal” eggs for freezing, and modifying the vitrification (flash freezing) process to yield birth rates per frozen egg more than 6 times higher than the current standard.

2009: Established the world’s first frozen egg bank storing exclusively CGH-tested donor eggs for dispensation to IVF patients.
2010: Birth of the first baby conceived from a CGH-tested egg supplied by the aforementioned donor egg bank.